Allergy Therapeutics (LON:AGY) Announces Quarterly Earnings Results

Allergy Therapeutics (LON:AGY) issued its quarterly earnings results on Monday. The company reported GBX (0.23) ($0.00) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a negative return on equity of 266.59% and a negative net margin of 72.86%.

Allergy Therapeutics Stock Down 8.2 %

LON AGY opened at GBX 5.92 ($0.08) on Wednesday. The company has a current ratio of 1.63, a quick ratio of 1.48 and a debt-to-equity ratio of 835.48. Allergy Therapeutics has a 12 month low of GBX 2.65 ($0.03) and a 12 month high of GBX 8 ($0.10). The stock’s 50 day moving average is GBX 6.57 and its 200 day moving average is GBX 5.92. The stock has a market cap of £290.97 million, a PE ratio of -5.71, a P/E/G ratio of -30.70 and a beta of 1.40.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.